Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943 | Chief Innovation Officer | August 09, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TREACE MEDICAL CONCEPTS, INC.
Report date August 09, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 679,863 |
Reported balance
After 2026-08-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-09 · Tax withholding · Disposed 9,814 · Balance 679,863 F1: Includes 463,167 restricted stock units. F2: Reflects the transfer of 15,000 shares of common stock to the reporting person's former spouse pursuant to a domestic relations order. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 463,167 restricted stock units.
F2: Reflects the transfer of 15,000 shares of common stock to the reporting person's former spouse pursuant to a domestic relations order.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2026 Filed Aug 12, 2026 22:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 9,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-347275 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 679,863 F1 · balance_after: Includes 463,167 restricted stock units. F2 · balance_after: Reflects the transfer of 15,000 shares of common stock to the reporting person's former spouse pursuant to a domestic relations order. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 1,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-102763 · ownership.xml · nonDerivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 704,677 F2 · balance_after: Includes 503,917 restricted stock units. Read SEC document |
| March 08, 2026 Filed Mar 12, 2026 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 401 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-102763 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 706,073 F1 · balance_after: Includes 509,648 restricted stock units. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,875 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001193125-26-047313 · ownership.xml · derivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,875 shares Expires 2027-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested in equal annual installments over 4 years, commencing on January 30, 2017 with the last installment vesting on January 30, 2021. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionCommon Stock | 16,875 | $1.05 | $17,718.75 |
DisclosureSEC source: 0001193125-26-047313 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 706,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 511, 291 restricted stock units. Read SEC document |
| January 22, 2026 Filed Jan 24, 2026 02:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 262,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-021450 · ownership.xml · nonDerivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 689,599 F2 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2027 and the last installment vesting on January 22, 2030; subject to Reporting Person's providing continued service to Issuer through each vesting date. F3 · balance_after: Includes 511,291 restricted stock units Read SEC document |
| January 21, 2026 Filed Jan 24, 2026 02:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionStock Option (Right to Buy) · Derivative | 53,500 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001193125-26-021450 · ownership.xml · derivative · entry 3 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,500 shares Expires 2026-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested in equal annual installments over 4 years, commencing on January 26, 2016 with the last installment vesting on January 26, 2020. Read SEC document |
| January 21, 2026 Filed Jan 24, 2026 02:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionCommon Stock | 53,500 | $0.72 | $38,520.00 |
DisclosureSEC source: 0001193125-26-021450 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 283,948 restricted stock units. Read SEC document |
| October 24, 2025 Filed Oct 28, 2025 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 208 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-253801 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,599 F1 · balance_after: Includes 283,948 restricted stock units. Read SEC document |
| August 09, 2025 Filed Aug 13, 2025 01:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 9,814 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-107555 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,807 F1 · balance_after: Includes 284,798 restricted stock units. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,437 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000950170-25-097601 · ownership.xml · derivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,437 shares Expires 2025-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested in equal annual installments over 4 years, commencing on July 28, 2015 with the last installment vesting on July 28, 2019. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionCommon Stock | 33,437 | $0.72 | $24,001.08 |
DisclosureSEC source: 0000950170-25-097601 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 325,098 restricted stock units. F2 · balance_after: Reflects the transfer of 13,897 shares of common stock to the reporting person's former spouse pursuant to a domestic relations order. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 01:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000950170-25-042291 · ownership.xml · derivative · entry 3 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,875 Underlying: Common Stock · 50,000 shares Expires 2027-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested in equal annual installments over 4 years, commencing on January 30, 2017 with the last installment vesting on January 30, 2021. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 01:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 50,000 | $7.97 | $398,460.00 |
DisclosureSEC source: 0000950170-25-042291 · ownership.xml · nonDerivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 364,081 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $7.8800 to $8.0900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 325,098 restricted stock units. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 01:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionCommon Stock | 50,000 | $1.05 | $52,500.00 |
DisclosureSEC source: 0000950170-25-042291 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 414,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Includes 325,098 restricted stock units. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 1,396 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-037572 · ownership.xml · nonDerivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,081 F2 · balance_after: Includes 325,098 restricted stock units. Read SEC document |
| March 08, 2025 Filed Mar 12, 2025 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 401 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-037572 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,477 F1 · balance_after: Includes 330,829 restricted stock units. Read SEC document |
| January 22, 2025 Filed Jan 25, 2025 02:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 140,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008973 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,878 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2026 and the last installment vesting on January 22, 2029; subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: Includes 332,473 restricted stock units. Read SEC document |
| January 10, 2025 Filed Jan 15, 2025 02:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 4,821 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-005580 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,253 F1 · balance_after: Includes 198,078 restricted stock units. F2 · balance_after: Reflects the transfer of 20,000 shares of common stock to the reporting person's former spouse pursuant to a domestic relations order. Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 20:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,750 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0000950170-24-106856 · ownership.xml · derivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,750 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested in equal annual installments over 4 years, commencing on December 15, 2014 with the last installment vesting on December 15, 2018. Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 20:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionCommon Stock | 33,750 | $0.10 | $3,280.50 |
DisclosureSEC source: 0000950170-24-106856 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 215,185 restricted stock units. Read SEC document |
| August 09, 2024 Filed Aug 10, 2024 01:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 120,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-095009 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,324 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in three equal annual installments on the first, second and third anniversaries of the grant date; subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: Includes 215,185 restricted stock units. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 1,396 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-030429 · ownership.xml · nonDerivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,424 F2 · balance_after: Includes 94,285 restricted stock units. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 389 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-030429 · ownership.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,820 F1 · balance_after: Includes 95,681 restricted stock units. Read SEC document |
| January 10, 2024 Filed Jan 13, 2024 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 73,200 | $0.00 Strike: $13.46 | $0.00 |
DisclosureSEC source: 0001209191-24-001589 · doc4.xml · derivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,200 Underlying: Stock Option (Right to Buy) · 73,200 shares Expires 2034-01-10 F3 · derivative.exercise_date: The stock option vests in equal annual installments over 4 years, with the first installment vesting on January 10, 2025 and the last installment vesting on January 10, 2028, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| January 10, 2024 Filed Jan 13, 2024 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 65,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001589 · doc4.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,209 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 10, 2025 and the last installment vesting on January 10, 2028; subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: Includes 96,070 RSUs. Read SEC document |
| November 02, 2023 Filed Nov 4, 2023 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 211 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054433 · doc4.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,184 F1 · balance_after: Includes 31,045 RSUs. Read SEC document |
| May 16, 2023 Filed May 19, 2023 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001209191-23-030857 · doc4.xml · derivative · entry 3 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 25,000 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The stock option vested in equal annual installments over 4 years, commencing on December 15, 2015 with the last installment vesting on December 15, 2018. Read SEC document |
| May 16, 2023 Filed May 19, 2023 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 25,000 | $25.44 | $635,977.50 |
DisclosureSEC source: 0001209191-23-030857 · doc4.xml · nonDerivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,395 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.0600 to $25.8000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 31,256 RSUs. Read SEC document |
| May 16, 2023 Filed May 19, 2023 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionCommon Stock | 25,000 | $0.10 | $2,500.00 |
DisclosureSEC source: 0001209191-23-030857 · doc4.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Includes 31,256 RSUs. Read SEC document |
| March 10, 2023 Filed Mar 11, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 51,950 | $0.00 Strike: $24.07 | $0.00 |
DisclosureSEC source: 0001209191-23-018042 · doc4.xml · derivative · entry 3 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,950 Underlying: Stock Option (Right to Buy) · 51,950 shares Expires 2033-03-10 F5 · derivative.exercise_date: The stock option will vest in equal annual installments over 4 years, commencing on March 10, 2024 with the last installment on March 10, 2027; subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| March 10, 2023 Filed Mar 11, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 22,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018042 · doc4.xml · nonDerivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,395 F3 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 10, 2024 with the last installment on March 10, 2027; subject to Reporting Person's providing continued service to Issuer through each vesting date. F4 · balance_after: Includes 31,256 RSUs. Read SEC document |
| March 09, 2023 Filed Mar 11, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 505 | $24.41 | $12,327.05 |
DisclosureSEC source: 0001209191-23-018042 · doc4.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,470 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · balance_after: Includes 8,331 RSUs. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.10 Strike: $0.10 | $2,500.00 |
DisclosureSEC source: 0001209191-23-010955 · doc4.xml · derivative · entry 3 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,750 Underlying: Common Stock · 25,000 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 25,000 | $21.69 | $542,235.00 |
DisclosureSEC source: 0001209191-23-010955 · doc4.xml · nonDerivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,975 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.5000 to $21.9900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 9,975 RSUs. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionCommon Stock | 25,000 | $0.10 | $2,500.00 |
DisclosureSEC source: 0001209191-23-010955 · doc4.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Includes 9,975 RSUs. Read SEC document |
| January 12, 2023 Filed Jan 14, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.10 Strike: $0.10 | $2,500.00 |
DisclosureSEC source: 0001209191-23-003385 · doc4.xml · derivative · entry 3 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,750 Underlying: Common Stock · 25,000 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 12, 2023 Filed Jan 14, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 25,000 | $25.57 | $639,307.50 |
DisclosureSEC source: 0001209191-23-003385 · doc4.xml · nonDerivative · entry 2 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,975 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.5000 to $25.7500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 9,975 RSUs. Read SEC document |
| January 12, 2023 Filed Jan 14, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionCommon Stock | 25,000 | $0.10 | $2,500.00 |
DisclosureSEC source: 0001209191-23-003385 · doc4.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Includes 9,975 RSUs. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.10 Strike: $0.10 | $2,500.00 |
DisclosureSEC source: 0001209191-22-057418 · doc4.xml · derivative · entry 3 Scanlan Sean F. · CIK 0001856371 · SVP, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,750 Underlying: Common Stock · 25,000 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 25,000 | $24.27 | $606,680.00 |
DisclosureSEC source: 0001209191-22-057418 · doc4.xml · nonDerivative · entry 2 Scanlan Sean F. · CIK 0001856371 · SVP, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,975 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.8000 to $24.5500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionCommon Stock | 25,000 | $0.10 | $2,500.00 |
DisclosureSEC source: 0001209191-22-057418 · doc4.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · SVP, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Includes 9,975 RSUs. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 22:03 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $9.83 | $0.00 |
DisclosureSEC source: 0001209191-22-054666 · doc4.xml · derivative · entry 2 Scanlan Sean F. · CIK 0001856371 · SVP, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2032-10-24 F3 · derivative.exercise_date: The stock option will vest in equal annual installments over 4 years, commencing on October 24, 2023 with the last installment on October 24, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 22:03 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 3,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-054666 · doc4.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · SVP, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,975 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on October 24, 2023 with the last installment on October 24, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: Includes 9,975 RSUs. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 01:26 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 50,650 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001567619-22-006733 · doc1.xml · derivative · entry 2 Scanlan Sean F. · CIK 0001856371 · SVP, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,650 Underlying: Common Stock · 50,650 shares Expires 2032-03-08 F3 · derivative.exercise_date: The stock option will vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 01:26 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 6,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006733 · doc1.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · SVP, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,575 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: Includes 6,575 RSUs. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:23 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001567619-22-006400 · doc1.xml · derivative · entry 3 Scanlan Sean F. · CIK 0001856371 · SVP, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,149 Underlying: Common Stock · 25,000 shares Expires 2028-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:23 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 25,000 | $20.82 | $520,550.00 |
DisclosureSEC source: 0001567619-22-006400 · doc1.xml · nonDerivative · entry 2 Scanlan Sean F. · CIK 0001856371 · SVP, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.35 to $21.09 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:23 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionCommon Stock | 25,000 | $1.05 | $26,250.00 |
DisclosureSEC source: 0001567619-22-006400 · doc1.xml · nonDerivative · entry 1 Scanlan Sean F. · CIK 0001856371 · SVP, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 22:08 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,873 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001567619-22-003261 · doc1.xml · derivative · entry 6 Scanlan Sean F. · CIK 0001856371 · SVP, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,149 Underlying: Common Stock · 3,873 shares Expires 2028-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.